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The aim of this study is to confirm the formation of inclusion complexes between bifonazole 
(BFZ) and different cyclodextrin (CD) derivatives. BFZ, an imidazole antifungal derivative, is a very hy-
drophobic compound, which is a major drawback in obtaining topical pharmaceutical formulations with 
optimal bioavailability. CDs may increase local drug delivery by enhancing the drug release and/or per-
meation. Several native and derivatized CD derivatives were tested in the experiments. The binary sys-
tems between BFZ and CDs were prepared in two molar ratios by physical mixing methods. The physico-
chemical properties of these complexes were studied by differential scanning calorimetry (DSC), Fourier 
transform infrared (FTIR) spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy methods. 
The results showed favorable molecular interaction between the components in solid state and in solution. 
1
H NMR-CD titrations and molecular modeling study showed that the most stable complex was obtained 
when using γ-CD. The Job’s method and 2D NMR spectroscopy support the 2 : 1 stoichiometry of the 
BFZ : γ-CD complex. 
 
Keywords: bifonazole; cyclodextrins; differential scanning calorimetry;  
Fourier transform infrared spectroscopy; 
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КАРАКТЕРИЗАЦИЈА НА ИНКЛУЗИОНИ КОМПЛЕКСИ МЕЃУ БИФОНАЗОЛ  
И РАЗЛИЧНИ ЦИКЛОДЕКСТРИНИ ВО ЦВРСТА СОСТОЈБА И ВО РАСТВОР 
 
Целта на ова истражување е да се потврди образувањето на инклузиони комплекси меѓу 
бифоназол (BFZ) и различни циклодекстрински (CD) деривати. BFZ, кој претставува имидазолски 
фунгициден дериват, е силно хидрофобно соединение, што претставува голем недостаток при 
добивање топични фармацевтски препарати со оптимална биорасположливост. CD може да ја 
зголеми локалната испорака на лекот со подобрување на ослободувањето и/или пропустливоста на 
лекот. Експериментално беа тестирани неколку нативни и дериватизирани CD. Бинарните системи 
меѓу BFZ и CD беа подготвени во два моларни односа со методи на физичко мешање. 
Физичкохемиските својства на овие комплекси беа испитувани со диференцијална скенирачка 
калориметрија (DSC), Фуриеова трансформна инфрацрвена (FTIR) спектроскопија и со нуклеарно-
магнетни резонантни спектроскопски методи. Резултатите покажуваат позитивна молекулска 
интеракција меѓу компонентите во цврста фаза и во раствор. Титрациите на 1H NMR–CD и 
испитувањето со молекулско моделирање покажуваат дека најстабилен комплекс се добива со 
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употреба на γ-CD. Методот на Job и 2D NMR спектроскопија ја потврдуваат 2:1 стехиометријата 
на комплексот BFZ : γ-CD. 
 
Клучни зборови: бифоназол; циклодекстрини; диференцијална скенирачка калориметрија;  
Фуриеова трансформна инфрацрвена спектроскопија; 1H NMR–CD титрации 
 
 
1. INTRODUCTION 
 
Bifonazole (BFZ) ((RS)-1-[phenyl(4-phe-
nylphenyl)methyl]-1H-imidazole) (Fig. 1) is a sub-
stituted imidazole antifungal agent that is structur-
ally related to other drugs from the azole group. It 
possesses a broad spectrum of activity in vitro 
against dermatophytes, molds, yeasts, dimorphic 
fungi, and some Gram-positive bacteria [1]. It has 
a double mechanism of action as it works by pre-
venting the 14-α-demethylation of 24-methylene-
dihydrolanosterol, consequently preventing the 
formation of the cellular membrane by inhibiting 
the production of ergosterol, and also causes direct 
damage to the membrane [2]. It also shows an anti-
inflammatory effect on erythema caused by hista-
mine [3, 4]. BFZ is available as 1% topical cream, 
powder, spray and lotion [5]. 
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Fig. 1. Constitutional formula and atom numbering of BFZ 
 
 
The therapeutic effectiveness of a drug de-
pends on its bioavailability and ultimately on the 
solubility of the drug molecule. Usually only solu-
bilized molecules can be absorbed by the cellular 
membrane to reach the specific site of drug action. 
Due to the imidazole cycle, BFZ is a basic com-
pound (pKa 9.30), and due to the presence of the 
aromatic rings it is a lipophilic substance (log P 
4.77) which is almost insoluble in water. BFZ has 
a water solubility of 0.7 μg/ml at 25 oC [6]. 
Solubility is one of the most important pa-
rameters for achieving a suitable concentration of 
drug in the systemic circulation to obtain an appro-
priate pharmacological response. To overcome this 
problem, various formulation strategies can be ap-
plied to increase the dissolution characteristics, 
such as solid dispersion, micronization, salt for-
mation, liquid–solid techniques, self-nanoemulsi-
fying drug delivery systems and cyclodextrin (CD) 
complexation [7, 8]. 
CDs are a family of cyclic oligosaccharides 
consisting of 6, 7, or 8 glucopyranose units, corre-
sponding to α-, β-, and γ-CDs respectively, with a 
hydrophilic outer surface and a lipophilic central 
cavity, used as complexing agents to increase the 
aqueous solubility of poorly soluble drugs and to 
increase their bioavailability and stability. The in-
troduction of hydrophobic moieties on the primary 
or secondary faces of native CDs gives them an am-
phiphilic character, enhances their inclusion capaci-
ty, and modifies their physicochemical properties. 
The concept of amphiphilic CDs is based on modu-
lation of the hydrophobic/hydrophilic balance of 
their construction and modulation of their self-
assembly properties through grafting of single or 
multiple substituents on the primary, secondary, or 
both faces of native CDs. Due to these features, CDs 
are able to form water-soluble inclusion complexes 
with many poorly soluble lipophilic drugs [9–12]. 
The formation of CD complexes is an equilib-
rium process where free "guest" molecules are in 
equilibrium with molecules in the complex [13]. In 
aqueous solution, the apolar CD cavity is occupied 
by water molecules which are energetically unstable, 
and therefore can be substituted by appropriate guest 
molecules, forming inclusion complexes [14–16]. 
The experimental methodology for the evaluation of 
the inclusion complexation of amphiphilic drugs with 
CDs includes the determination of association equi-
librium constants for the inclusion process [17, 18]. 
Thermoanalytical techniques (differential 
scanning calorimetry, DSC; thermogravimetry) are 
frequently used in the investigation of the thermal 
properties of CDs and their inclusion complexes 
[19, 20].  
In previously published articles, inclusion 
complexes of azole derivatives with CDs in aque-
ous solution and in the solid phase were studied by 
solubility methods, spectroscopy, thermal analysis, 
and X-ray diffractometry, and their modes of inter-
action were assessed. The importance of the hy-
drophobicity of the guest molecule and the spatial 
relationship between host and guest molecules 
were clearly reflected in the magnitude of the sta-
bility constant of the inclusion complexes [21, 22]. 
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A nuclear magnetic resonance (NMR) spectro-
scopic study was published in order to evaluate the 
complexation of fluconazole with β-CD, and the re-
sults confirmed the formation of an inclusion com-
plex in aqueous solution [23, 24]. Complexes of BFZ 
and miconazole prepared with different CDs by vari-
ous methods such as kneading, co-evaporation, and 
physical mixing were characterized by Fourier trans-
form infrared spectroscopy (FTIR) and DSC studies, 
and the effect of complexationon the dissolution rate 
of BFZ was studied [25, 26]. 
The purpose of this study is to evaluate the 
possibility of interaction of the antifungal drug 
BFZ through complexation with different types of 
CDs. Binary system of BFZ and different CDs 
were prepared in two molar ratios, 1 : 1 and 2 : 1 
(BFZ : CD), using the physical mixing method. 
The resulting complexes were characterized 
by means of DSC thermal analysis, FTIR, NMR 
spectroscopy (
1
H-NMR) and molecular modeling.  
To determinate the complex stability and 
stoichiometry, 
1
H-NMR-CD titrations were carried 
out. The stoichiometry of the complexes was con-
firmed by the Job’s method of continuous variation 
[27]. To explore the geometry of the inclusion 
complex, 2D COSY spectra were recorded [28]. 
 
 
2. EXPERIMENTAL 
 
2.1. Materials 
 
BFZ of pharmaceutical grade was acquired 
from Richter Gedeon (Târgu Mureș, Romania); 
D2O was purchased from Sigma-Aldrich (Germa-
ny). All the CD derivatives were acquired from 
Cyclolab Ltd (Budapest, Hungary). The following 
CDs were used in this study: α-, β-, and γ-CDs, 
randomly methylated-α-CD (RAME-α-CD), ran-
domly methylated-β-CD (RAMEB), randomly me-
thylated-γ-CD (RAMEγ-CD), hydroxypropyl-β-CD 
(HPβ-CD), hydroxypropyl-γ-CD (HPγ-CD), sulfobu-
tyl ether-α-CD (SBE-α-CD), sulfobutyl ether-β-CD 
(SBE-β-CD), and sulfate-β-CD (S-β-CD). Other 
chemicals of analytical grade were obtained from 
commercial suppliers and used without further purifi-
cation. Ultrapure water produced using a Milli-Q 
system (Millipore, USA) was used in all experiments. 
 
2.2. Methods 
 
2.2.1. Differential scanning calorimetry 
 
The temperature and enthalpy measurements 
were performed using a Mettler Toledo DSC 823e 
Thermal Analysis system (Schwerzenbach, Swit-
zerland). Approximately 1–2 mg of the active ma-
terial or binary systems was examined in alumi-
num pans between 25 and 400 °C in a nitrogen 
atmosphere with a flow rate of 50 ml/min. The 
heating rate was 10 °C/min. 
 
2.2.2. Fourier-transform infrared spectroscopy 
 
FTIR analysis allowed the detection of in-
clusion complexation because the diffraction and 
infrared (IR) spectra patterns of the complex must 
be clearly distinct from those resulting from the 
super imposition of individual diffraction and IR 
spectra patterns. The IR spectra of BFZ, different 
CD derivatives, and their binary systems were rec-
orded using an FTIR 470 Plus, (AbleJasco, Japan) 
spectrometer. The resolution was 4 cm
–1
, the wave 
number range was 2000–400 cm–1, and the scan 
number was 64. The samples were embedded in 
KBr pellets. Analyses were performed at room 
temperature. 
 
2.2.3. Nuclear мagnetic resonance (1H-NMR) 
spectroscopy 
 
NMR spectroscopy has been recognized as an 
important tool for the interaction study of CD and 
pharmaceutical compounds in solution state. This 
technique also gives information on the topology of 
the interaction between analyte and CDs, not only 
furnishing information on the structure of inclusion 
complexes but also allowing the stoichiometry and 
association or binding constant of guest : CD com-
plexes to be derived [29]. 2D COSY and ROESY 
experiments are important in CD-related studies, as 
they complement each other; COSY provides infor-
mation on the coupling of protons, while 2D ROESY 
gives the same information through space [30].  
To determine the complex stoichiometry and 
stability, 
1
H-NMR-CD titrations were carried out. 
The stoichiometry of the complexes was evaluated 
by Job’s method of continuous variation [31]. 
 
2.2.3.1. 
1
H-NMR-CD-titrations 
 
All measurements were effectuated on a Var-
ian VNMR spectrometer (600 MHz for 
1
H). Spectra 
were recorded at 25 ºC and referenced to internal 
Na-acetate. Titrations were carried out in a medium 
at pH 2.0, which was reached with a buffer solution 
containing 0.1 M HCl, 0.05 M KCl, and 500 μl 
D2O. A stock solution containing 0.01 M BFZ was 
prepared in water and methanol and 1 mg of Na-
acetate was added. The stock for the CDs was 0.015 
M. Next, 30 µl of the BFZ stock solution was mixed 
with different volumes of CD stock solution, the 
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appropriate background media were added to give a 
total volume of 600 µl, and 
1
H-NMR spectra were 
recorded. Solvent signals were suppressed with the 
water excitation technique (WET) sequence. 
 
2.2.3.2. Determination of complex stoichiometry 
 
Solutions were prepared from BFZ and the 
CDs with concentrations of 2 mM in 5 v/v% meth-
anol and the medium at pH 2.0, respectively. The 
solutions were mixed in different ratios. After that, 
1
H-NMR spectra were recorded, which were refer-
enced to internal dimethyl sulfoxide (DMSO). 
 
2.2.3.3. Determination of the structure  
of inclusion complexes formed 
 
Solutions containing 5 mM BFZ and 2.5 
mM CD in methanol were examined. The struc-
tures of the complexes were determined with 2D 
COSY experiments. 
 
2.2.4. Molecular modeling studies 
 
Molecular modeling studies were performed 
using HyperChem 8.0 software (HyperChem (TM) 
Professional 8.0, Hypercube Inc., USA). BFZ, the 
CDs, and the complexes were geometrically opti-
mized using the molecular mechanics method 
(MM+ force field, Polak-Ribiere algorithm, RMS 
gradient  0.01). One or two molecules of BFZ 
were put manually into the cavity of each CD with 
the phenyl or imidazole rings inside and the com-
plexes were optimized geometrically using the 
same parameters as described before. 
The formation energy (E) was calculated 
with the formula: 
 
           (               )  (1) 
 
where Ecomplex, ECD, and Ebifonazole represent the min-
imum energy of the complexes, the CDs, and BFZ, 
respectively. Negative formation energy shows a 
thermodynamically favored complex; the most sta-
ble conformation is indicated by the higher for-
mation energy [32, 33]. 
 
3. RESULTS AND DISCUSSION 
 
3.1. Differential scanning calorimetry 
 
Differences in the thermal behavior of BFZ, 
BFZ-CDs, and the corresponding inclusion com-
plexes were evident. As shown in Figure 2, BFZ 
exhibits a characteristic endothermic fusion peak at 
152.47 °C corresponding to the BFZ melting point.  
 
 
 
 
Fig. 2. DSC thermograms of BFZ, CDs, and complexes 
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Furthermore, β-CD, γ-CD, HP-β-CD, and 
RAMEB show broad endothermic events in the 
range from 30 to 95 °C, which are related to the 
loss of adsorbed water, and small endo- or exo-
effects at 210–325 °C due to thermal degradation. 
DSC thermograms of the physical mixture for BFZ 
and α-, β, and γ-CDs show the existence of the 
endothermic peak of BFZ, indicating interactions 
between the CDs and BFZ. The BFZ peak in the 
physical mixture with γ-CD is increased, indicating 
a more intense interaction of BFZ with γ-CD. The 
DSC thermograms of BFZ-γ-CD 2:1 complexes 
show the disappearance of the BFZ endothermic 
peak at 152.47 °C. In the binary systems of BFZ 
with RAMEB and HP-β-CD, the complete 
disappearance of the BFZ endothermic peak can be 
observed, indicating a more intense interaction of 
BFZ with RAMEB or HP-β-CD. The absence of the 
characteristic peak of the drug is strong evidence for 
the inclusion of the drug in the CD cavity. This 
could be attributed to the formation of an 
amorphous solid dispersion, to the molecular 
encapsulation of the drug into the CD cavity, or 
both. 
 
3.2. Fourier transform infrared spectroscopy 
 
The FTIR spectra of BFZ presented in 
Figure 3 reveal numerous absorption bands in the 
fingerprint region. 
The most intense peaks in the spectrum of 
BFZ are due to the imidazole ring (1000–650 cm–1, 
1680–1640 cm–1) and the relationship between 
aliphatic carbon and N of the imidazole cycle (CN 
stretch), but the characteristic aromatic cycles can 
also be observed (1600–1585 cm–1).  
Amongst the characteristic bands are 2850–
3000 cm
–1 
C-H bonds in the imidazole ring and 
three aromatic rings (Fig. 3).  
In the spectrum of -CD there is a wide 
absorption band in the 1200–1000 cm–1 area, 
attributed to the glucopyranosic ring. Another 
broad and strong absorption band in the 3000 cm
–1
 
domain is attributed to OH stretching. For the 
binary systems, the 1600–600 cm–1 domain was 
chosen to highlight the modification of spectra due 
to complexation. Having a photo- protective 
character, CDs mask the characteristic peaks of 
groups that are included in their cavities.  
The presence of the imidazole ring in the 
frequency characteristics of the absorption 
spectrum of the complex in the 1000–650 cm–1 
range and assigned to the link between the carbon 
atom of the imidazole ring and N in the 1200–1070 
cm
–1 
range indicates that this ring has not been 
encapsulated in the cavity. Some peaks attributed 
to the three cycles in the aromatic structure 
disappear in BFZ complexes formed with β-CD, 
which indicates that a part of the aromatic rings 
was encapsulated (Fig. 3). 
The disappearance of characteristic frequen-
cies of the imidazole ring from the absorption 
spectra of the complexes in the range of 1000–650 
cm
–1
 indicates that it entered the ring cavity of the 
HP-β-CD. Together with the imidazole ring, the 
aliphatic carbon atom bonded to the N of the 
imidazole and a part of the close aromatic cycle 
was also encapsulated (Fig. 4). 
 
 
 
  
 
Fig. 3. FTIR spectra of BFZ (left) and -CD complex (right).  
(BFZ is marked in blue, β-CD in green, and the complex in red.) 
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Fig. 4. FTIR spectra of BFZ complexes with HP-β-CD (left) and with RAMEB (right). 
(BFZ is marked in blue, CD in green, and the complex in red.) 
 
 
 
 
 
Fig. 5. FTIR spectra of BFZ complexes with α-CD (left) and with-CD (right). 
(BFZ is marked in blue, CD in green, and the complex in red.) 
 
 
For the binary systems, the 1600–600 cm–1 
domain was chosen to highlight the modification 
of spectra due to complexation. The presence of 
the imidazole ring in the frequency characteristics 
of the absorption spectrum of BFZ--CD complex 
indicates that this ring has not been encapsulated in 
the cavity. The peaks attributed to the three 
aromatic cycles disappear from the complexes 
formed with BFZ and -CD, indicating that a part 
of the aromatic rings was encapsulated (Fig. 5).  
More evidence of complex formation was 
obtained by FTIR spectroscopic investigation of 
the bands corresponding to the functional groups 
of BFZ involved in the complexation. 
 
3.3. NMR assignments of BFZ 
 
The assignment of the signals was based on 
chemical shifts by 2D 
1
H-
13
C HSQC and HMBC 
measurements. The values are listed in Table 1. 
 
 
 
T a b l e  1 
 
1
H chemical shifts of BFZ 
 
 
Nucleus H-1 H-2 H-3 H-4 H-5,9 H-6,8,7 H-10,18 H-11,17 H-12,16 H-13,15 H-14 
δ (ppm) 8.38 7.56 7.48 6.84 7.13 7.32 7.16 7.53 7.34 7.49 7.28 
Characterization of inclusion complexes between bifonazole and different cyclodextrins in solid and solution state 
Maced. J. Chem. Chem. Eng. 36 (1), 81–91 (2017) 
87 
3.4. Stability of the complexes 
 
The observed chemical shift of a specified 
nucleus is the weighted average of the non- com-
plexed and complexed forms: 
 
o b s
B F Z B F Z B F Z C D B F Z C D 
          (2) 
 
The molar fractions can be expressed by the 
formula for the stability constant: 
 
[ B F Z C D ]
K
[ B F Z ][C D ]


  (3) 
 
where [BFZ – CD], [BFZ], and [CD] are the equi-
librium concentrations of the complex, BFZ, and 
CD, respectively. None of the equilibrium concen-
trations can be measured directly; only the analyti-
cal concentrations ([BFZ]T and [CD]T) are known 
values. Since the analytical concentrations are: 
 
T
[ B F Z ] [ B F Z ] [ B F Z C D ]     (4) 
 
T
[C D ] [C D ] [ B F Z C D ]     (5) 
 
the concentration of the complex can be expressed 
by the analytical concentrations of BFZ and CD by 
introducing the terms and rearranging Eq. (3):
 
2
T T T T T T
1 1
[ B F Z ] [C D ] [ B F Z ] [C D ] 4[ B F Z ] [C D ]
K K
[ B F Z C D ]
2
 
      
 
 
              (6) 
 
The molar fractions of the free and com-
plexed BFZ are: 
 
T
B F Z
T
B F Z C D
T
[ B F Z ] [ B F Z C D ]
[ B F Z ]
[ B F Z C D ]
[ B F Z ]

 
 

 
      (7) 
Combining Eqs. (2), (6) and (7), the ob-
served chemical shift of a given nucleus can be 
expressed using the analytical concentrations of 
BFZ and CD: 
 
2
T T T T T T
o b s
T
B F Z
1 1
[ ] [C D ] [ B F Z ] [C D ] 4[ B F Z ] [C D ]
K K
2[ B
B
F Z
Z
]
F
 
     
 
     
 
(8) 
 
where           B F Z C D B F Z
     
. 
 
Since the [BFZ]T was kept constant during 
the titration, the stability constant and the chemical 
shifts were calculated by nonlinear parameter fit-
ting of Eq. (8) to the δobs versus [CD]T datasets. 
The values of stability constants, expressed in 
logK, for the CDs are listed in Table2. 
 
 
  T a b l e  2  
 
Stability constants for the inclusion complexes of BFZ in logK units 
 
 1 2 3 4 5 6 7 8 9 10 
CD β-CD γ-CD 
RAME-α-
CD 
RAME- β-
CD 
RAME- γ-
CD 
HP- β-
CD 
HP- γ-
CD 
SBE- 
α-CD 
SBE- 
β-CD 
S- β-CD 
logK 3,57 6,45 1,98 3,43 4,23 3,66 6,23 3,59 3,94 3,11 
± 0,02 0,07 1,37 0,02 1,38 0,02 0,02 0,54 0,05 0,02 
 
 
In the case of the complexes BFZ:HP-γ-CD 
and BFZ:γ-CD, we can observe that the values of 
the stability constants are approximately double the 
other values, which indicates the presence of an-
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other type of inclusion complex with these two 
CDs, with a stoichiometry of 2:1. This theory was 
confirmed by other methods too. 
 
3.4.1. Stoichiometry of the inclusion complexes 
 
The stoichiometry of the CD complexes was 
determined by the continuous variation method of 
Job [21], where the chemical shift changes (Δδ) 
weighted by the molar fraction of BFZ were plot-
ted depending on the molar fraction of BFZ. 
 
 
 
 
Fig. 6. Job’s plot of selected BFZ proton in the complex  
of BFZ-γ-CD 
 
The maxima of the chemical shifts of the 
complexes occur when the molar fraction is 0.5, 
indicating 1:1 stoichiometry for the complexes, 
which is the most common form of CD complex. 
Another type of complex appears with γ-CD, 
where the maxima of the chemical shifts of the 
complexes occur when the molar fraction is 0.6, 
which indicates a stoichiometry of 2:1 (Fig. 6). 
 
3.4.2. Structure of the inclusion complexes 
 
The structures of the inclusion complexes 
were investigated for BFZ with two CDs: β-CD and 
γ-CD, by the 2D 1H-1H COSY method. There were 
clear cross-peaks between H-5,9 (7.23 ppm) and H-
6,8 (7.38 ppm) protons of BFZ and the protons (3.58 
and 3.68 ppm) of β-CD, which indicates that the phe-
nyl ring of BFZ stays in the CD cavity (Fig. 7).  
In the complex of BFZ:γ-CD with a stoichi-
ometry of 2:1, the biphenyl ring stays inthe cavity 
(Fig. 8). This fact is demonstrated by the clear 
cross-peaks between the protons of the CD (3.25 
ppm, 3.37 ppm) and the protons of BFZ from the 
biphenyl ring (H-10,18: 7.21 ppm; H-12,16: 7.26 
ppm) (Fig. 9). 
 
 
 
Fig. 7. Part of the 1H-1H COSY spectrum of the complex of BFZ-β-CD 
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Fig. 8. Molecular modeling representation of the BFZ--CD 2:1 (a); BFZ-β-CD 2:1 (b); BFZ--CD 1:1 (c);  
and BFZ-α-CD 1:1 (d) complexes. (Green: γ-CD; light blue: carbon; dark blue: nitrogen.) 
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3.5. Molecular modeling studies 
 
Based on the values of the formation ener-
gies, the most stable complex is formed in the case 
of -CD, when two molecules of BFZ are inserted 
into the cavity of the CD.  
The energy minimized structure of the 
BFZ:γ-CD 2:1 complex is shown in Figure 8. 
The highest formation energies were –17.86, 
–12.79, –10.90, –10.75, and –4,64 kcal/mol in the 
cases of BFZ--CD 2:1, BFZ-β-CD 2:1, BFZ-β-CD 
1:1,BFZ--CD 1:1, and BFZ-α-CD 1:1, respective-
ly, indicating that BFZ complexes of the natural 
CDs are more stable than those of the chemically 
modified CDs. The energy minimized structures of 
these complexes are shown in Figure 8 (hydrogen 
depleted structure). 
 
 
4. CONCLUSIONS 
 
This study demonstrated the establishment 
of favorable molecular interaction between the 
BFZ and the CDs in both solid state and solution. 
It was revealed that the properties of the products 
of CDs with BFZ are influenced by the nature of 
the CD.  
Changes in the FTIR spectra such as a shift 
of the characteristic absorption bands of BFZ, the 
disappearance or reduction of intensity, and the 
appearance of new bands might be related to pos-
sible drug–CD interactions.  
The DSC analysis supports the hypothesis of 
the formation of partial inclusion complexes be-
tween BFZ and most of the studied CDs; further-
more, for γ-CD or HP-β-CD, the complexation 
proved to be total.  
The stoichiometry of the inclusion complexes 
depends on the size of the CD cavity. With the α- 
and β-CDs, BFZ : CD complexes have a 1:1 stoi-
chiometry, whereas with γ-CD, BFZ : CD complex-
es present a 2:1 stoichiometry; the BFZ : γ-CD 
complexes exhibited very high stability constants.  
These data can be utilized for improved BFZ 
drug formulations. 
 
Acknowledgments. This work was supported by the 
Transylvanian Museum Society and Semmelweis University, 
Faculty of Pharmacy research grant no. 128./P.2. EMEO-
GYSZ 2014. 
 
REFERENCES 
 
[1] T. E. Lackner, S. P. Clissold, Bifonazole. A Review of 
its antimicrobial activity and therapeutic use in su-
perficial mycoses, Drugs, 38 (2), 204–225 (1989). 
 
[2] D. Berg, K. H. Büchel, M. Plempel, E. Regel, Antimy-
cotic sterol biosynthesis inhibitors, Trends in Pharma-
cology Sciences, 7, 233–238 (1986).  
DOI: 10.1016/0165-6147(86)90330-5 
 
[3] H. Petri, H. Tronnier, P. Haas, Investigations into the 
anti-inflammatory effect of bifonazole, In: Hay R. J. 
(ed.). Advances in Topical Antifungal Therapy, Springer 
Verlag, Berlin, 26–31, 1986. 
 
[4] L. Hegemann, S. M. Toso, K. I. Lahijani, G. F. Webster, 
J. Ditto, Direct interaction of antifungal azole-
derivatives with calmodulin: a possible mechanism for 
their therapeutic activity, Journal of Investigative Der-
matology, 100 (3), 343–346 (1993).  
DOI: 10.1111/1523-1747.ep12470043 
 
[5] A. P. Tiziani, Havard's Nursing Guide to Drugs, Else-
vier Health Sciences, 2010. 
 
[6] http://pubchem.ncbi.nlm.nih.gov/compound/2378#sectio
n=Computed-Properties 
 
[7] J. T. Lalwani, V. T Thakkar, H. V. Patel, Enhancement 
of solubility and oral bioavailability of ezetimibe by a 
novel solid self nano-emulsifying drug delivery system 
(SNEDDS), International Journal of Pharmacy and 
Pharmaceutical Sciences, 5 (3), 513–522 (2013). 
 
[8] K. S. G. Arulkumaran, J. Padmapreetha, Enhancement 
of solubility of ezetimibe by liquisolid technique, Inter-
national Journal of Pharmaceutical Chemistry and 
Analysis, 1 (1), 14–38 (2014). 
 
[9] L. Zerkoune, S. Lesieur, J. L. Putaux, L. Choisnard, A. 
Geze, D. Wouessidjewe, B. Angelov, C. Verbert-Nardin, 
J. Doutch, A. Angelova, Mesoporous self-assembled na-
noparticles of biotransesterified cyclodextrins and 
nonlamellar lipids as carriers of water-insoluble sub-
stance, Soft Matter, 12, 7359–7350 (2016).  
DOI: 10.1039/c6sm00661b 
 
[10] L. Zerkoune, A. Angelova, S. Lesieur, Nano-assemblies 
of modified cyclodextrins and their complexes with 
guest molecules: incorporation in nanostructured mem-
branes and amphiphilenanoarchitectonics design, Nano-
materials, 4 (3), 741–765 (2014).  
DOI: 10.3390/nano4030741 
 
[11] A. Angelova, B. Angelov, R. Mutafchieva, S. Lesieur, 
Biocompatible mesoporous and soft nanoarchitectures, 
Journal of Inorganic and Organometalic Polymers., 25, 
214–232 (2015). DOI:10.1007/s10904-014-0143-8 
 
[12] A. Angelova, C. Fajolles, C. Hocquelet, F. Dejedaini-
Pilard, S. Lesieur, V. Bonet, B. Perly, G. Lebas, L. Mau-
claire, Physico-chemical investigation of asymmetrical 
peptidolipidyl-cyclodextrin, Journal of Colloid Interface 
Science, 322, 304–314 (2008).  
DOI: 10.1016/j.jcis.2008.03.023 
 
[13] T. Loftsson, D. Duchene, Cyclodextrins and their phar-
maceutical applications, International Journal of Phar-
maceutics, 329, 1–11 (2007).  
DOI: 10.1016/j.ijpharm.2006.10.044 
 
[14] T. Loftsson, B. J. Ólafsdóttir, H. Fridriksdottir, S. 
Jonsdottir, Cyclodextrin complexation of NSAIDs: 
physicochemical characteristics, European Journal of 
Pharmaceutical Sciences, 1 (2), 95–101(1993). 
 
[15] E. M. Dell Valle, Cyclodextrins and their uses: A re-
view, Process Biochemistry, 39, 1033–1046 (2004).  
DOI: 10.1016/S0032-9592(03)00258-9 
Characterization of inclusion complexes between bifonazole and different cyclodextrins in solid and solution state 
Maced. J. Chem. Chem. Eng. 36 (1), 81–91 (2017) 
91 
[16] J. Szejtli, The cyclodextrins and their applications in 
biotechnology, Carbohydrate Polymers, 12, 375–392 
(1990). 
 
[17] A. Angelova, C. Ringard-Lefebvre, A. Baszkin, Drug-
cyclodextrin association constants determined by surface 
tension and surface pressure measurements. I. Host-
guest complexation of water soluble drugs by cyclodex-
trins: polymyxin B – beta-cyclodextrin system, Journal 
of Colloid Interface Science, 212, 275–279 (1999).  
DOI: 10.1006/jcis.1999.6088 
 
[18] A. Angelova, C. Ringard-Lefebvre, A. Baszkin, Drug-
cyclodextrin association constants determined by surface 
tension and surface pressure measurements. II. Seques-
tration of water insoluble drugs from the air/water inter-
face: Retinol beta-cyclodextrin system, Journal of Col-
loid Interface Science, 212, 280–285 (1999).  
DOI: 10.1006/jcis.1999.6089 
 
[19] P. J. Mura, Analytical techniques for characterization of 
cyclodextrin complexes in the solid state: A review. 
Journal of Pharmaceutical and Biomedical Analysis, 
113, 226–238 (2015). 
DOI: 10.1016/j.jpba.2015.01.058 
 
[20] G. Yurtdas, M. Demirel, L. Genc, Inclusion complexes 
of fluconazole with β-cyclodextrin: physicochemical 
characterization and in vitro evaluation of its formula-
tion, Journal of Inclusion Phenomena and Macrocyclic 
Chemistry, 70 (3–4), 429–435 (2011).  
DOI: 10.1007/s10847-010-9908-z 
 
[21] C. Trandafirescu, A. Gyeresi, Z. Szabadai, M. Kata, Z. 
Aigner, Solid-state characterization of bifonazole-beta-
cyclodextrinbinary systems. Note I., Farmacia, 62 (3), 
513–523 (2014). 
 
[22] R. Singh, N. Bharti, J. Madan, S. N. Hiremath, Charac-
terization of cyclodextrin inclusion complexes. A re-
view, Journal of Pharmaceutical Science and Technolo-
gy, 2 (3), 171–183 (2010). 
 
[23] G. Orgován, H. Kelemen, B. Noszál, Protonation and β-
cyclodextrin complex formation equilibria of flucona-
zole, Journal of Inclusion Phenomena and Macrocyclic 
Chemistry, 84 (3–4), 189–196 (2016).  
DOI: 10.1007/s10847-016-0595-2 
 
[24] J. Li, S. Zhang, Y. Zhou, S. Guan, L. Zhang, Inclusion 
complexes of fluconazole with β-cyclodextrin and 2-
hydroxypropyl-β-cyclodextrin in aqueous solution: 
preparation, characterization and a structural insight, 
Journal of Inclusion Phenomena and Macrocyclic 
Chemistry, 84 (3–4), 209–217 (2016).  
DOI: 10.1007/s10847-010-9908-z 
 
[25] G. Popović, M. Čakar, The effects of β-cyclodextrin and 
pH on bifonazole hydrosolubility, Journal of the Serbian 
Chemical Society, 69 (3), 225–231(2004). 
 
[26] H. Gupta, K. Kar, Solid state compatibility studies of 
miconazole using thermal and spectroscopic methods, 
Advances in Analytical Chemistry, 5 (3), 51–55 (2015). 
DOI: 10.5923/j.aac.20150503.01. 
 
[27] P. Job, Job’s method of continuous variation, Ann. 
Chim., 9, 113–120 (1928). 
 
[28] N. Marangoci, M. Mares, M. Silion, A. Fifere, C. Var-
ganici, A. Nicolescu, C. Deleanu, A. Coroaba, M. Pin-
teala, B. C. Simionescu, Inclusion complex of a new 
propiconazole derivative with β-cyclodextrin: NMR, 
ESI–MS and preliminary pharmacological studies, Re-
sults in Pharma Sciences, 1 (1), 27–37 (2011).  
DOI: 10.1016/j.rinphs.2011.07.001 
 
[29] J. Szejtli, Cyclodextrins and Their Inclusion Complexes, 
Akadémiai Kiadó, Budapest, 1982. 
 
[30] P. J. Hore, Nuclear Magnetic Resonance. Oxford Uni-
versity Press, Oxford, 98–101, 1995. 
 
[31] Facchiano, R. Ragone, Modification of Job’s method for 
determining the stoichiometry of protein–protein com-
plexes, Analytical Biochemistry, 313, 170–172 (2003). 
 
[32] S. K. Upadhyay, G. Kumar, NMR and molecular model-
ling studies on the interaction of fluconazole with β-
cyclodextrin, Chemistry Central Journal, 3 (1), (2009). 
DOI:10.1186/1752-153X-3-9 
 
[33] S. R. Arsad, H. Maarof, I. W. Wan, H. Y. Aboul-Enein, 
Theoretical and molecular docking study of ketocona-
zole on heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin as 
chiral selector, Chirality, 28 (3), 209–214 (2016). 
DOI:10.1002/chir.22554 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
